included $988 million of ICD sales. On a pro forma
basis for 2006 -- as though the Company had acquired Guidant on January 1,
2006 -- CRM sales were $2.026 billion, which included $1.473 billion of ICD
sales. U.S. CRM sales in 2007 were $1.371 billion, which included $1.053
billion of ICD sales, as compared to U.S. CRM sales of $908 million, which
included $696 million of ICD sales. Pro forma U.S. CRM sales were $1.358
billion, which included $1.053 billion of ICD sales. International CRM
sales in 2007 were $753 million, which included $489 million of ICD sales,
as compared to international CRM sales of $463 million, which included $292
million of ICD sales. Pro forma international CRM sales were $668 million,
which included $420 million of ICD sales.
Reported net loss for 2007 was $495 million, or $0.33 per share.
Reported results for 2007 included acquisition, divestiture, litigation and
restructuring-related charges, and amortization expense (pre-tax) of $1.9
billion, or $1.10 per share, which consisted of:
-- $560 million, primarily non-cash, associated with the write down of
goodwill in connection with business divestitures;
-- $85 million in-process research and development write offs, related
primarily to the Company's acquisition of Remon Medical Technologies,
-- $37 million related to the Company's acquisition of Guidant;
-- $365 million attributable to estimated potential losses associated with
patent litigation involving the Company's Interventional Cardiology
-- $184 million of restructuring charges associated with the Company's
expense and head count reduction initiatives; and
-- $641 million of amortization expense.
Adjusted net income for 2007, excluding these charges and amortization
expense, was $1.2 billion, or $0.77 per share.
Reported net loss for 2006 was $3.6 billion, or $2.81 per share.
Reported results for 200
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Related biology technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved
. Boston Scientific to Participate in Merrill Lynch Conference2
. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium3
. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses4
. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program5
. Boston Scientific Announces Results for Third Quarter Ended September 30, 20076
. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA7
. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-68
. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator9
. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board10
. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results11
. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute